Neoadjuvant immunology therapy in patients with non-small cell lung cancer and chronic obstructive pulmonary disease.

Very good pathological response was also achieved with neoadjuvant immunotherapy in NSCLC patients with combined COPD, with MPR and pCR of 55.6% and 38.9%, respectively, compared with 53.8% and 28.2% in non-COPD patients, but the differences in MPR and pCR between the two subgroups did not reach statistical significance (P=0.90 and P=0.42, respectively).

also in 111,027 other papers